 So there were 5,300 participants in the trial, a mix of cisgender women and adolescent girls across the two countries. And about 2,100 of them received this injection of linacapavir. And the early results from that trial showed that none of those women or girls contracted HIV during this period, which is just unheard of in these kinds of studies and really, really encouraging.